A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators are testing improvement in survival outcomes in DIPG
patients when stratified with MR perfusion score and treated with the said protocol. Newly
diagnosed DIPG patients will undergo MRI perfusion study in addition to the usual MRI at
diagnosis and will be stratified into hyperperfused or hypoperfused tumours.
The hyperperfused patients will receive additional low dose Bevacizumab weekly with
conventional standard radiotherapy.
The hypo-perfused patients will receive ultra-low-dose radiotherapy fractionation equivalent
to conventional RT biological dose.